Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a daily pill stop hereditary angioedema attacks?

NCT ID NCT05047185

Disease control Sponsor: Pharvaris Netherlands B.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial tests whether an experimental oral medication, deucrictibant, can reduce the number of swelling attacks in people with hereditary angioedema (HAE) types I and II. Participants take either a low or high dose of the drug or a placebo for 12 weeks, and then may continue on the drug in an open-label phase. The goal is to see if the drug safely lowers the monthly rate of confirmed HAE attacks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deucrictibant (PHA-022121), an oral medication taken daily to prevent swelling attacks
What this could lead to
If successful, this could lead to a convenient daily pill that reduces the frequency of painful and potentially dangerous swelling attacks in people with hereditary angioedema.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug may also have side effects or prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

34 people

The number who actually took part.

Started

Apr 2022

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed and dated informed consent form * Diagnosis of HAE type I or II * Documented history of at least 3 HAE attacks within the last 3 consecutive months prior to screening, or a minimum of 2 HAE attacks during the screening period * Reliable access and experience to use standard of care acute attack medications Exclusion Criteria: * Pregnancy or breast-feeding * Clinically significant abnormal electrocardiogram * Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study * Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrolment * Abnormal hepatic function * Abnormal renal function * History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse * Participation in any other investigational drug study within defined period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C1 esterase inhibitor deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

C1 inhibitor deficiency hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2 Hereditary Angioedema Types I and II hereditary angioedema with C1Inh deficiency angioedema prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C1 esterase inhibitor deficiency C1 inhibitor deficiency Hereditary angioedema Hereditary angioedema - type 1 Hereditary angioedema - type 2 Hereditary angioedema attack Hereditary angioedema type I Hereditary angioedema type II Hereditary angioedema types I and II Hereditary angioedema with C1 esterase inhibitor deficiency

Contacts and locations

Locations

  • Study Site

    Vienna, A-1090, Austria

  • Study site

    Birmingham, Alabama, 35209, United States

  • Study site

    Paradise Valley, Arizona, 85253, United States

  • Study site

    St Louis, Missouri, 63141, United States

  • Study site

    Sofia, 1680, Bulgaria

  • Study site

    Ottawa, Ontario, K1H 1E4, Canada

  • Study site

    Montreal, Quebec, H2W 1R7, Canada

  • Study site

    Berlin, 10117, Germany

  • Study site

    Frankfurt, 60323, Germany

  • Study site

    Dublin, D08NHY1, Ireland

  • Study site

    Padua, PD, 35128, Italy

  • Study site

    Milan, 20157, Italy

  • Study site

    Palermo, 0146, Italy

  • Study site

    Krakow, Poland

  • Study site

    Brighton, England, BN2 1ES, United Kingdom

  • Study site

    Bristol, England, BS10 5NB, United Kingdom

  • Study site

    Cambridge, England, CB2 0QQ, United Kingdom

  • Study site

    London, England, E1 1FR, United Kingdom

  • Study site

    Southampton, England, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.